Glaukos' iDose TR Shows Stronger IOP Reduction in Glaucoma Trial
Event summary
- Glaukos' Phase 4 trial showed iDose TR reduced mean diurnal IOP by 11.1 mmHg when combined with cataract surgery, compared to 7.4 mmHg with surgery alone.
- The study achieved statistical significance (p<0.0001) with a clinically meaningful incremental treatment effect of 3.6 mmHg.
- iDose TR demonstrated a favorable safety profile with no treatment-related adverse events of corneal endothelial cell loss or cystoid macular edema.
- The trial randomized 149 study eyes, with 74 assigned to the iDose TR group and 75 to the control group.
The big picture
Glaukos' positive Phase 4 trial results for iDose TR reinforce its position in the glaucoma treatment landscape. The study's success highlights the potential for procedural pharmaceuticals to address patient non-compliance issues with topical medications. This aligns with broader industry trends toward long-duration, intracameral therapies that improve treatment adherence and outcomes for chronic eye diseases.
What we're watching
- Market Adoption
- How quickly iDose TR can gain traction in combination with cataract surgery, expanding its use beyond standalone procedures.
- Regulatory Dynamics
- Whether the positive Phase 4 results will accelerate regulatory approvals or expand indications for iDose TR.
- Competitive Positioning
- The pace at which Glaukos can differentiate iDose TR from existing glaucoma treatments and topical medications.
Related topics
